Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Akouos, Inc.

Surveyor Capital

Wu Capital

Cormorant Asset Management

Fidelity Management and Research Company

Novartis Venture Fund

Pivotal bioVenture Partners

Polaris Founders Capital

RA Capital Management

New Enterprise Associates

Akouos

We love spooky season! Check out these scenes from last month's Halloween party. Costumes were encouraged, and our team members showcased their incredible creativity.
 
The Best Costume Award went to Grace Cook, Samantha Davis took home the Most Original Costume Award, and Heather Devantier won the "I Wish I Had Thought of That" Award! Many thanks to all who participated and made the day so fun!
 
If you’re interested in joining the Akouos family, we encourage you to visit https://lnkd.in/g5w8FE6t to browse our current job openings and apply online.
 
#TeamAkouos #Halloween

Even the rain couldn’t keep the fun away! Members of our team and their families got together for a memorable fall outing at Kimball Farm. The team connected over a meal and drinks, ice cream, and some exhilarating bumper car action. Thank you to each and every one of you who came out to spend time together! Looking to be part of the Akouos team? Click the link below to explore our career opportunities!

#TeamAkouos

https://lnkd.in/g5w8FE6t

Celebrate the power of STEM with us this National STEM Day! Our mission of making healthy hearing available to all drives us forward every day. If you're looking for an opportunity to work on cutting-edge projects and contribute to meaningful advancements in medicine, explore our career openings and consider joining our dynamic team: https://lnkd.in/g5w8FE6t

#NationalSTEMDay #STEMDay #STEMImpact #STEMCommunity

Earlier this month, the Akouos team participated in the #Walk4Hearing! Each year we are honored to walk in solidarity with the deaf and hard of hearing community as we share our commitment to our mission to make healthy hearing available to all.

Click through to see some memories from this year’s walk and years past!


#NEWalk4Hearing

Akouos is excited to attend the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels, Belgium. We look forward to connecting with experts from around the world at these two engagements:

Aaron Tward, Chief Scientific Officer, will be presenting an update on “Considerations in the Development of a Gene Therapy for Otoferlin Gene-mediated Hearing Loss.”

Additionally, Katherine Gribble will be presenting on "The Efficiency of Multiplexing Guide RNAs for Multi-gene CRISPR/CaS9-based Genomic Modulation" at P696 during the poster sessions.
 
#ESGCT
 

	Dec '18	Dec '19	Dec '20	Dec '21
net income	-6.01M -	-25.74M 328.09%	-48.60M 88.80%	-86.67M 78.34%
depreciation and amortization	55K -	697K 1,167.27%	2.17M 212.05%	3.75M 72.28%
deferred income tax
stock based compensation	22K -	138K 527.27%	4.50M 3,157.25%	9.48M 110.92%
change in working capital	241K -	3.14M 1,201.24%	882K 71.88%	7.99M 805.90%
accounts receivables
inventory
accounts payables	74K -	-76K 202.70%	583K 867.11%	385K 33.96%
other working capital	167K -	3.21M 1,823.35%	299K 90.69%	7.61M 2,443.48%
other non cash items	-1.04M -	2.26M 317.31%	281K 87.57%	1.72M 512.10%
net cash provided by operating activities	-6.74M -	-19.51M 189.68%	-40.77M 108.95%	-63.73M 56.33%
investments in property plant and equipment	-532K -	-3.44M 546.62%	-4.53M 31.77%	-9.02M 98.96%
acquisitions net
purchases of investments			-268.85M -	-161.36M 39.98%
sales maturities of investments			29.50M -	288.00M 876.27%
other investing activites
net cash used for investing activites	-532K -	-3.44M 546.62%	-243.88M 6,989.51%	117.62M 148.23%
debt repayment	-22K -	-99K 350%	-253K 155.56%	-378K 49.41%
common stock issued			227.27M -	406K 99.82%
common stock repurchased	-110K -			35K -
dividends paid
other financing activites	24.98M -	25.10M 0.50%	101.48M 304.25%	154K 99.85%
net cash used provided by financing activities	24.85M -	25.00M 0.64%	328.50M 1,213.74%	217K 99.93%
effect of forex changes on cash
net change in cash	17.58M -	2.06M 88.31%	43.85M 2,034.01%	54.11M 23.38%
cash at beginning of period	6.76M -	24.34M 260.06%	26.39M 8.44%	70.25M 166.15%
cash at end of period	24.34M -	26.39M 8.44%	70.25M 166.15%	124.36M 77.02%
operating cash flow	-6.74M -	-19.51M 189.68%	-40.77M 108.95%	-63.73M 56.33%
capital expenditure	-532K -	-3.44M 546.62%	-4.53M 31.77%	-9.02M 98.96%
free cash flow	-7.27M -	-22.95M 215.81%	-45.30M 97.39%	-72.75M 60.60%

COM:AKOUOS

Akouos

Last Close

13.29

30/11 21:00

Volume Today

1.79M

Avg: -

Preview